ClinicalTrials.gg
CompletedNCT00325468Updated Aug 1, 2017Results posted

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

A Phase 3 interventional study of AMG 162 in Low Bone Mineral Density, sponsored by Amgen. Completed. Open to female participants. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.

Enrollment
11th of 25
200 · median 100
Started
2006
with 1 other
Phase 3
13 of 25
none open now
Registered
4th of 25
by date
Lead sponsor
12 of 25
Amgen

Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 11th largest by enrollment, is one of 2 that started in 2006, is one of 13 in phase 3, and was the 4th registered.

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing denosumab in Bone Diseases, Metabolic, or all of them as a file.
02

Study summary

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density

03

Conditions studied

  • Low Bone Mineral Density

Keywords

  • bone loss
  • osteoporosis
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be ambulatory
  • Subject must have atteneded the 20010223 end-of-study visit and have completed all tests and procedures during the end-of-study visit
  • signed must be obtained before any study-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Experienced severe and/or serious adverse event which were thought to be related to denosumab administration during the 20010223 study.
  • Developed grade 3 or 4 laboratory abnormalities based on v3.0 during the 20010223 study which did not normalized upon follow up or did not have diagnosis or treatment.
  • Newly diagnosed conditions such as hyper/hypo thyroidism, rheumatoid arthritis, other bone diseases, renal disease.
  • Using therapies while participating in the 20010223 study such as oral bisphosphonates, calcitonin, oral strontium, SERMS, systemic glucocortiocosteriods.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    AMG 162

    AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42

    Drug: AMG 162

Interventions

  • AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8

    Time frame: 8 years

  2. Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8

    Time frame: 8 years

  3. Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8

    Time frame: 8 years

Secondary outcomes

  1. Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8

    Time frame: 8 years

  2. Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8

    Time frame: 8 years

07

Results

Posted Jul 30, 2013

Participant flow

Subjects who successfully completed the double-blind, randomized, 4-year dose-ranging parent study 20010223

Participant flow — Overall Study
MilestonePlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Started23171412422
Completed1212109014
Not completed1154348
Withdrew: Adverse event11051
Withdrew: Death20240
Withdrew: Lost to follow-up00122
Withdrew: Physician decision11010
Withdrew: Withdrawal by subject310144
Withdrew: Site closure etc42181

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame:
8 years
Reported as:
Least squares mean · percent
Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
percentPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Lumbar Spine Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 88.4 (4.4 to 12.4)11.2 (7.2 to 15.2)11.0 (6.0 to 16.0)16.5 (14.9 to 18.1)12.4 (8.5 to 16.4)
SecondaryBone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame:
8 years
Reported as:
Median · percent
Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8
percentPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Bone-Specific Alkaline Phosphatase Percent Change From Parent Study 20010223 Baseline to Year 8-55.8 (-66.7 to -24.4)-44.7 (-63.6 to -23.8)-52.5 (-60.4 to -27.1)-44.4 (-61.9 to -10.2)-54.2 (-65.1 to -24.9)
PrimaryTotal Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame:
8 years
Reported as:
Least squares mean · percent
Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
percentPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Total Hip Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 81.1 (-1.2 to 3.5)4.3 (2.0 to 6.6)2.3 (-0.5 to 5.1)6.8 (5.8 to 7.7)3.4 (1.1 to 5.7)
PrimaryDistal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame:
8 years
Reported as:
Least squares mean · percent
Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8
percentPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Distal 1/3 Radius Bone Mineral Density Percent Change From Parent Study 20010223 Baseline to Year 8-5.2 (-7.4 to -2.9)1.4 (-0.9 to 3.8)0.6 (-1.9 to 3.1)1.3 (0.5 to 2.2)-2.2 (-4.3 to -0.1)
SecondarySerum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8
Time frame:
8 years
Reported as:
Median · percent
Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8
percentPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QW
Serum C-Telopeptide Percent Change From Parent Study 20010223 Baseline to Year 8-66.4 (-90.8 to -27.3)-72.0 (-84.9 to -57.4)-48.0 (-87.9 to 26.8)-64.6 (-77.3 to -2.7)-49.8 (-82.0 to -45.4)

Adverse events

Collected over 48 months (i.e., 4 years during the 20050233 extension study). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/23 (13%)18/23 (78.3%)
Denosumab 210 mg Q6M—3/17 (17.6%)15/17 (88.2%)
Denosumab 30 mg Q3M—5/14 (35.7%)13/14 (92.9%)
Denosumab Continuous Treatment—31/124 (25%)106/124 (85.5%)
Alendronate 70 mg QW—3/22 (13.6%)19/22 (86.4%)
All Participants—45/200 (22.5%)171/200 (85.5%)
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70 mg QWAll Participants
OsteoarthritisMusculoskeletal and connective tissue disorders0/231/173/140/1240/224/200
Hypochromic anaemiaBlood and lymphatic system disorders0/230/171/140/1240/221/200
Angina unstableCardiac disorders0/230/171/140/1240/221/200
Coronary artery diseaseCardiac disorders0/230/171/141/1240/222/200
Coronary artery stenosisCardiac disorders0/230/171/140/1240/221/200
Colonic stenosisGastrointestinal disorders0/230/171/140/1240/221/200
DeathGeneral disorders0/230/171/140/1240/221/200
PneumoniaInfections and infestations0/230/171/142/1240/223/200
Fibula fractureInjury, poisoning and procedural complications0/230/171/140/1240/221/200
Traumatic brain injuryInjury, poisoning and procedural complications0/230/171/140/1240/221/200
Most frequent other events
Showing 10 of 148
Most frequent other events
EventPlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70 mg QWAll Participants
Upper respiratory tract infectionInfections and infestations9/237/172/1424/1243/2245/200
ArthralgiaMusculoskeletal and connective tissue disorders4/234/174/1420/1245/2237/200
HypertensionVascular disorders2/233/174/1413/1243/2225/200
BronchitisInfections and infestations2/234/173/147/1241/2217/200
Back painMusculoskeletal and connective tissue disorders3/234/171/1414/1243/2225/200
Pain in extremityMusculoskeletal and connective tissue disorders2/234/170/1414/1243/2223/200
Procedural painInjury, poisoning and procedural complications2/230/173/147/1243/2215/200
DepressionPsychiatric disorders3/233/170/146/1242/2214/200
Muscle spasmsMusculoskeletal and connective tissue disorders4/230/171/147/1241/2213/200
Musculoskeletal painMusculoskeletal and connective tissue disorders4/230/171/149/1240/2214/200

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QWTotal
Mean65.8 ± 9.165.8 ± 9.468.0 ± 7.265.8 ± 7.066.6 ± 8.966.1 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QWTotal
Female23171412422200
Male000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QWTotal
White or Caucasian18161211220178
Black or African American001203
Hispanic or Latino5118217
Asian000101
Japanese000101
American Indian or Alaska Native000000
Native Hawaiian or Other Pacific Islander000000
Aborigine000000
Other000000
Baseline Bone Mineral Density T-score of Each Anatomic Site
Baseline Bone Mineral Density T-score of Each Anatomic Site(T-score)PlaceboDenosumab 210 mg Q6MDenosumab 30 mg Q3MDenosumab Continuous TreatmentAlendronate 70mg QWTotal
Lumbar spine BMD T-score-2.36 ± 0.62-2.02 ± 1.16-1.29 ± 0.94-1.35 ± 0.87-1.64 ± 1.09-1.55 ± 0.96
Total hip BMD T-score-1.63 ± 0.75-1.39 ± 0.67-1.05 ± 0.75-1.08 ± 0.68-1.50 ± 0.81-1.21 ± 0.73
Distal 1/3 radius T-score-1.91 ± 1.25-1.45 ± 0.98-1.14 ± 1.29-1.23 ± 1.21-1.57 ± 0.98-1.35 ± 1.19
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011 Feb;96(2):394-402. doi: 10.1210/jc.2010-1805. Epub 2010 Dec 15. PubMed 21159841 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2006 to primary completion in Mar 2011, 58 months.

Results were first posted in Jul 2013, 2 years 4 months after primary completion.

Of 26 phase 3 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2006
First posted
May 12, 2006
StartActual
May 1, 2006
Primary completionActual
Mar 28, 2011
CompletionActual
Aug 2, 2012
Results first posted
Jul 30, 2013
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00325468
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 12, 2006
Start date
May 1, 2006
Primary completion
Mar 28, 2011
Completion
Aug 2, 2012
Results posted
Jul 30, 2013
Last update
Aug 1, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion